Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Johnson and Johnson buys FemRx in expansion of women's health business

This article was originally published in Clinica

Executive Summary

Johnson & Johnson is to buy women's health company FemRx for around $22 million in cash. The move will boost J&J's women's health business, which makes products for the treatment of a diversified range of gynaecological and urological disorders. FemRx has had a difficult year, beginning with job cuts and, more recently, the threat of delisting from the Nasdaq national market.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts